I'm pleased to say that, today (20 June 2020) the Oxford Vaccine, aimed at raising immunity against COVID-19, is reported to be looking promising from the results of phase 1 and 2 studies. It provokes a strong antibody and strong T-cell response in triallists while causing no serious ill effects.

The vaccine would now move to phase 3 multicentre trials.